00320_3_CHD_B_Hospital_Rates

First Page		Document Content
Date: 2014-04-30 13:01:40 Pharmacology Research Bioethics Medical ethics Design of experiments Human respiratory syncytial virus Palivizumab Placebo Clinical trial Medicine Science Clinical research		00320_3_CHD_B_Hospital_Rates Add to Reading List Source URL: www.rsvfacts.com Download Document from Source Website File Size: 56,12 KB Share Document on Facebook

	Palivizumab Prophylaxis — Alaska, 2015–16 RSV Season DocID: 1l7Yf - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYNAGIS safely and effectively. See full prescribing information for SYNAGIS. SYNAGIS® (palivizumab) injection, for DocID: 1gqM3 - View Document
	Guidelines for Prophylaxis for RSV Infections in High-Risk Infants in Hawaii  (Developed by Consensus Committee – June 25, 2014 and Revised based on the New AAP RSV Policy Statement) 1. All children with chronic lun DocID: 19Sru - View Document
	NEIL ABERCROMBEE PATRICIA MCMANAMAN GOVERNOR DocID: 19HQA - View Document
	www.prembaby.org.au Respiratory Syncytial Virus (RSV) What is Respiratory Syncytial Virus (RSV) RSV is the most common cause of lower-respiratory-tract infection in infancy or childhood. RSV is highly contagious. Approx DocID: 17WQP - View Document